

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6594192

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
LIANSHENG LI	06/12/2018
TAO WU	06/12/2018
JUN FENG	06/12/2018
PINGDA REN	06/18/2018
YI LIU	06/12/2018
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	KURA ONCOLOGY, INC.
<b>Street Address:</b>	3033 SCIENCE PARK ROAD
<b>Internal Address:</b>	SUITE 220
<b>City:</b>	SAN DIEGO
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	92121
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	16619423
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(650)493-6811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(650) 493-9300
<b>Email:</b>	melissa.sanchez@wsgr.com, patentdocket@wsgr.com
<b>Correspondent Name:</b>	WILSON SONSINI GOODRICH & ROSATI
<b>Address Line 1:</b>	650 PAGE MILL ROAD
<b>Address Line 4:</b>	PALO ALTO, CALIFORNIA 94304
<b>ATTORNEY DOCKET NUMBER:</b>	47535-721.831
<b>NAME OF SUBMITTER:</b>	MELISSA SANCHEZ
<b>SIGNATURE:</b>	/Melissa Sanchez/
<b>DATE SIGNED:</b>	03/10/2021
<b>Total Attachments: 2</b>	

source=47535\_721\_831\_Executed PCT Assignment (Kura)#page1.tif

source=47535\_721\_831\_Executed PCT Assignment (Kura)#page2.tif

WHEREAS, the undersigned:

- |  |                                       |  |  |
|--|---------------------------------------|--|--|
| 1. Liansheng LI<br>San Diego, CA 92130<br>US | 2. Tao Wu<br>Carlsbad, CA 92009<br>US | 3. Jun FENG<br>San Diego, CA 92130<br>US | 4. Pingda REN<br>San Diego, CA 92130<br>US |
| 5. Yi LIU<br>San Diego, CA 92130<br>US       |                                       |  |  |

(hereinafter "Inventor(s)"), have invented certain new and useful improvements in

**METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS**

☒ for which PCT application serial number PCT/US2018/036485 was filed on June 7, 2018 in the US Receiving Office of the Patent Cooperation Treaty, which claims priority to application serial number 62/517,041 filed on June 8, 2017 and application serial number 62/636,976 filed on March 1, 2018

(hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, Kura Oncology, Inc., a corporation formed under the laws of the State of Delaware, having a place of business at 3033 Science Park Road, Suite 220, San Diego, CA 92121 US, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

PATENT ASSIGNMENT		Docket Number 47535-721601
Date: <u>6/12/2018</u> <u>[Signature]</u> Liansheng Li	Date: <u>06/12/2018</u> <u>[Signature]</u> Tao Wu	
Date: <u>6/12/2018</u> <u>[Signature]</u> Jun Feng	Date: <u>06/18/2018</u> <u>[Signature]</u> Pingda Ren	
Date: <u>6/12/2018</u> <u>[Signature]</u> Yi Liu		
RECEIVED AND AGREED TO BY ASSIGNEE: Kura Oncology, Inc.		
Date: <u>6/18/2018</u>	Signature: <u>[Signature]</u> Name: Annette North Title: SVP, General Counsel Kura Oncology, Inc.	